Gdnf fusion polypeptides and methods of use thereof

SI3538560T1Active Publication Date: 2026-08-31KEROS THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
SI201731664
Authority / Receiving Office
SI · SI
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-11-10
Filing Date
2017-11-09
Publication Date
2026-08-31
Estimated Expiration
2037-11-09

AI Technical Summary

Technical Problem

Current therapeutic options for obesity and related metabolic diseases such as Type-1 and Type-2 diabetes are limited, with a need for novel treatments that effectively address insulin resistance and adipocyte-related complications.

Method used

Development of GDNF fusion polypeptides, which include an Fc domain, albumin-binding peptide, fibronectin domain, or human serum albumin joined to a GDNF variant, providing long serum half-life and binding affinity to GFRα1, used in pharmaceutical compositions and methods for treating obesity and Type-1 and Type-2 diabetes, as well as neurological diseases.

Benefits of technology

The GDNF fusion polypeptides demonstrate extended serum half-life and binding affinity, effectively reducing body weight, adiposity, and improving glucose clearance without affecting appetite or lean mass, offering a novel approach to treating metabolic and neurological disorders.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
Need to check novelty before this filing date? Find Prior Art